Company: MDCXW
Filing Date: 2025-11-19
Form Type: S-1
Source: 0001062993-25-016962
Chunk: 13

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-19
Form: S-1
Chunk 13
---
2,680,000 common shares underlying the Private Warrants                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Terms of the offering                         | The Selling Shareholder will determine when and how it will dispose of any common shares registered under this prospectus for sale.                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Common shares to be outstanding               | 24,709,144 common shares                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Use of Proceeds                               | We will not receive any proceeds from the sale of the common shares offered by this prospectus by the Selling Shareholder. However, we may receive up to $10,050,000 in aggregate gross proceeds from the exercise of Private Warrants from time to time by the Selling Shareholder. This prospectus does not relate to the exercise of such Private Warrants.                                                                                                                                                                                                                                      |
| Voting rights                                 | Each outstanding common share will be entitled to one vote on all matters submitted to a vote of shareholders.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Listing                                       | Our common shares are listed on the Nasdaq under the symbol "MDCX".                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dividend policy                               | We do not anticipate that we will declare or pay dividends in the foreseeable future on our common shares. Instead, we anticipate that all of our earnings will be used for the operation and growth of our business. Any future determination to declare cash dividends would be subject to the discretion of our board of directors and would depend upon various factors, including our results of operations, financial condition and liquidity requirements, restrictions that may be imposed by applicable law and our contracts and other factors deemed relevant by our board of directors. |
| Risk factors                                  | See "Risk Factors" and the other information included in this prospectus for a discussion of factors you should consider before deciding to invest in our securities.                                                                                                                                                                                                                                                                                                                                                                                                                               |

Except as otherwise noted, all information contained in this prospectus assumes no exercise of our outstanding options (as described herein) or warrants (other than the Private Warrants). The number of common shares that will be outstanding after this offering is based on 22,029,144 common shares outstanding as of November 7, 2025, and assumes the complete exercise of all of the Private Warrants.

<div align='center'>6

SELECTED HISTORICAL CONSOLIDATED FINANCIAL INFORMATION</div>

The following tables set forth our selected historical consolidated financial information. You should read the selected historical consolidated financial information in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements and